Advertisement

Thyroid Eye Disease (TED)

  • Jeffrey NeradEmail author
  • Trevor Smith
Chapter
  • 47 Downloads

Abstract

Thyroid eye disease is an autoimmune condition with an active and inactive phase resulting in proptosis, eyelid retraction, and periorbital edema of varying severity. Symptoms range from mild eye irritation to vision loss from compressive optic neuropathy requiring medical and possibly acute surgical intervention. Active disease typically lasts one to three years before burn-out occurs; reactivation and irreversible vision loss is uncommon. An ophthalmologist can be of unique benefit to the patient in three valuable ways: (1) early diagnosis and referral for systemic treatment, (2) protection against the vision threatening effects of the disease, and (3) restoration of the patient’s natural appearance.

Keywords

Graves’ ophthalmopathy Graves’ orbitopathy Thyroid-associated orbitopathy Graves’ disease Immunotherapy Orbital radiotherapy Rituximab Teprotumumab Decompression Thyroid eye disease 

Suggested Readings

  1. 1.
    Bartley GB, Fatourechi V, Kadrmas EF, JACOBSEN SJ, Ilstrup DM, Garrity JA, Gorman CA. Clinical features of Graves’ ophthalmopathy in an incidence cohort. Am J Ophthalmo. 1996;121(3):284–90.Google Scholar
  2. 2.
    Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol. 1997;47(1):9–14.Google Scholar
  3. 3.
    Barrio-Barrio J, Sabater AL, Bonet-Farriol E, Velázquez-Villoria Á, Galofré JC. Graves’ ophthalmopathy: VISA versus EUGOGO classification, assessment, and management. J Ophthalmol. 2015;2015.Google Scholar
  4. 4.
    Perros P, Neoh C, Dickinson J. Thyroid eye disease. BMJ. 2009;6(338):b560.CrossRefGoogle Scholar
  5. 5.
    Clinical Features—VISA Classification—Thyroid Eye Disease [Internet]. International Thyroid Eye Disease Society. http://thyroideyedisease.org/clinical-features-visa-classification (2019). Accessed 10 Apr 2019.
  6. 6.
    Vestergaard P. Smoking and thyroid disorders–a meta-analysis. Eur J Endocrinol. 2002;146(2):153–61.CrossRefGoogle Scholar
  7. 7.
    Gillespie EF, Smith TJ, Douglas RS. Thyroid eye disease: towards an evidence base for treatment in the 21st century. Curr Neurol Neurosci Rep. 2012;12(3):318–24.CrossRefGoogle Scholar
  8. 8.
    Bartalena L, Marcocci C, Bogazzi F, Panicucci M, Lepri A, Pinchera A. Use of corticosteroids to prevent progression of Graves’ ophthalmopathy after radioiodine therapy for hyperthyroidism. New Engl. J Med. 1989;321(20):1349–52.Google Scholar
  9. 9.
    Bradley EA, Gower EW, Bradley DJ, Meyer DR, Cahill KV, Custer PL, Holck DE, Woog JJ. Orbital radiation for graves ophthalmopathy: a report by the American Academy of Ophthalmology. Ophthalmology. 2008;115(2):398–409.CrossRefGoogle Scholar
  10. 10.
    Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA, Harris GJ, Antonelli A, Salvi M, Goldberg RA, Gigantelli JW. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017;376(18):1748–61.CrossRefGoogle Scholar
  11. 11.
    Nerad JA. Techniques in ophthalmic plastic surgery: a personal tutorial. Elsevier Health Sciences; 11 Nov 2009.Google Scholar
  12. 12.
    Tomsak MR, EL Toukhy R.E. Thyroid ophthalmopathy: levine. In: Nerad J, Grossinklaus H, editors. Ophthalmology clinics of North American, vol. 9. No. 4. WB Saunders; December 1996.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Cincinnati Eye InstituteCincinnatiUSA

Personalised recommendations